4D Molecular Therapeutics Q2 net loss widens to $28.1M; cash runway into 2025; expands 4D-310 trial to females

4D Molecular Therapeutics, Inc.

2022-Q2 EPS reported -$1.69 revenue$1,382,000

Net loss of $28.1M in Q2 2022 vs $7.6M in Q2 2021; revenue fell to $0.2M from $14.6M.
Cash and equivalents of $261.6M as of June 30, 2022, expected to fund operations into first half 2025.
R&D expenses rose to $20.4M from $15.2M; G&A to $8.2M from $7.0M.
4D-310 Phase 1/2 expanded to include female Fabry patients; new steroid-sparing immunosuppression cohort added; data update expected 1H 2023.
Five clinical-stage candidates on track for multiple clinical data updates in 2023.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.